Design, synthesis, and biological evaluation of pyrazole-based combretastatin A-4 analogues as potential cytotoxic agents

被引:0
作者
Omar, Mai H. [1 ]
Emam, Soha H. [1 ]
Mikhail, Demiana S. [1 ]
Elmeligie, Salwa [1 ]
机构
[1] Cairo Univ, Fac Pharm, Dept Pharmaceut Organ Chem, POB 11562,33 Kasr El Aini St, Cairo 11562, Egypt
关键词
CA-4; CBSIs; Tubulin; Pyrazole; 2-pyrazoline; Cytotoxic activity; Apoptosis; ROS; ANTINEOPLASTIC AGENTS; COLCHICINE SITE; DERIVATIVES; ANTICANCER; ANTIBACTERIAL; TUBULIN; APOPTOSIS; BINDING;
D O I
10.1016/j.bioorg.2025.108691
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The design of pyrazole-based combretastatin A-4 analogues 4a-g depended on preservation of the cis olefinic configuration of combretastatin A-4 (CA-4) by replacing it with a pyrazole ring, aiming to enhance the cytotoxic activity. Furthermore, the pyrazoline moiety of 4a-g was included to add a polar center for binding interactions and to contribute to apoptosis induction. Synthesis of pyrazoline derivatives 4a-g was achieved through a new chalcone analogues 3a-g and were confirmed by spectral data and high-resolution mass spectroscopy. The cytotoxic activity was the intended biological target of the new compounds, and upon preliminary in vitro investigation against the NCI-60 panel at one dose, and it was found that the pyrazoline derivative 4a showed remarkable growth inhibition against fifteen cancer cell lines. Also, the cytotoxic activity of compounds 4a-g was screened in vitro against non-small cell lung cancer cell line A549 and ovarian cancer cell line OVCAR-4, along with the normal lung cell line WI-38, and their half-maximal inhibitory concentration (IC50) values were calculated. Compound 4a was found to be the most potent cytotoxic agent (IC50 = 3.46 and 5.93 mu M against OVCAR-4 and A549 cells, respectively) and the most selective derivative towards A549 cells with a selectivity index equal to 7.2. The inhibition of tubulin polymerization by the most active compound, 4a, was comparable to CA-4 and was visualized by means of immunofluorescent staining of A549 cells. Prediction of reactive oxygen species (ROS) production by pyrazole-pyrazoline hybrid 4a was confirmed as a rise of ROS level by compound 4a was observed to be almost 243 %- in respect to control-and ROS scavenger enzyme catalase inhibited apoptotic cell death induced by 4a by 10.5 %. Moreover, compound 4a caused a decline of the mitochondrial membrane potential by approximately 56 % less than the control, which confirms the presence of ROS. The apoptotic cell death by 4a was further studied, and it showed a 3.7-folds elevation of caspase-3 expression compared to the control. Additionally, a molecular docking study of compound 4a into the colchicine binding site of tubulin confirmed the anti-tubulin activity. Indeed, pyrazoline derivative 4a is a promising new druggable molecule that acts as a tubulin polymerization inhibitor and ROS-mediated apoptosis-inducing agent.
引用
收藏
页数:26
相关论文
共 115 条
[61]   Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings [J].
Lipinski, CA ;
Lombardo, F ;
Dominy, BW ;
Feeney, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :3-25
[62]  
Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
[63]   Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation [J].
Liu, Wei ;
He, Youyou ;
Guo, Zhongjie ;
Wang, Miaomiao ;
Han, Xiaodong ;
Jia, Hairui ;
He, Jin ;
Miao, Shanshan ;
Wang, Shengzheng .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01)
[64]   Caspase-3-mediated GSDME activation contributes to cisplatin- and doxorubicin-induced secondary necrosis in mouse macrophages [J].
Mai, Feng-Yi ;
He, Pengyan ;
Ye, Jie-Zhou ;
Xu, Li-Hui ;
Ouyang, Dong-Yun ;
Li, Chen-Guang ;
Zeng, Qiong-Zhen ;
Zeng, Chen-Ying ;
Zhang, Cheng-Cheng ;
He, Xian-Hui ;
Hu, Bo .
CELL PROLIFERATION, 2019, 52 (05)
[65]   Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones [J].
Malebari, Azizah M. ;
Morales, Gabriela Duffy ;
Twamley, Brendan ;
Fayne, Darren ;
Khan, Mohemmed Faraz ;
McLoughlin, Eavan C. ;
O'Boyle, Niamh M. ;
Zisterer, Daniela M. ;
Meegan, Mary J. .
PHARMACEUTICALS, 2022, 15 (09)
[66]  
Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041
[67]   Synthesis and Biological Evaluation of Novel 2-Aroyl Benzofuran-Based Hydroxamic Acids as Antimicrotubule Agents [J].
Mariotto, Elena ;
Canton, Martina ;
Marchioro, Chiara ;
Brancale, Andrea ;
Hamel, Ernest ;
Varani, Katia ;
Vincenzi, Fabrizio ;
De Ventura, Tiziano ;
Padroni, Chiara ;
Viola, Giampietro ;
Romagnoli, Romeo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
[68]   An Update on the Nitrogen Heterocycle Compositions and Properties of US FDA-Approved Pharmaceuticals (2013-2023) [J].
Marshall, Christopher M. ;
Federice, John G. ;
Bell, Chloe N. ;
Cox, Philip B. ;
Njardarson, Jon T. .
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (14) :11622-11655
[69]   A bioavailability score [J].
Martin, YC .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (09) :3164-3170
[70]   Exploring the modulatory influence on the antimalarial activity of amodiaquine using scaffold hybridisation with ferrocene integration [J].
Mbaba, Mziyanda ;
Golding, Taryn M. ;
Omondi, Reinner O. ;
Mohunlal, Roxanne ;
Egan, Timothy J. ;
Reader, Janette ;
Birkholtz, Lyn-Marie ;
Smith, Gregory S. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 271